
|Videos|October 13, 2017
What is the Advantage of Administering a Beta-Lactam with a Beta-Lactamase Inhibitor?
Author(s)Contagion® Editorial Staff
Amanda Paschke, MD, MSCE, explains the advantage of administering a beta-lactam in combination with a beta-lactamase inhibitor.
Advertisement
Amanda Paschke, MD, MSCE, director of Clinical Research, Infectious Diseases, at Merck, breaks down the advantages of administering a beta-lactam in combination with a beta-lactamase inhibitor. Dr. Paschke highlights Merck’s development compound imipenem-relebactam, and explains how relebactam restores susceptibility to imipenem.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contagion Live
1
Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Meets Primary Endpoint in Phase 3 Study
2
Zoliflodacin Emerges as a First-in-Class Oral Option Against Drug-Resistant Gonorrhea
3
Caring Holistically: NYU’s Approach to Pediatric Infectious Disease
4
FDA Approves Zoliflodacin for Uncomplicated Urogenital Gonorrhea
5

















































































































































































































































































